What is FEMSelect?
FEMSelect specializes in the development and deployment of EnPlace, a proprietary, minimally invasive treatment designed to address Pelvic Organ Prolapse. The company operates at the intersection of medical device innovation and patient-centric care, providing a streamlined, same-day treatment option that facilitates rapid recovery. By focusing on a condition that significantly impacts the daily lives of women over 50, FEMSelect has established a robust market position as a provider of high-impact, evidence-based healthcare solutions. Their business model integrates clinical education with advanced procedural technology, ensuring that both healthcare providers and patients are equipped with the necessary resources to manage and treat prolapse effectively.
How much funding has FEMSelect raised?
FEMSelect has raised a total of $9M across 1 funding round:
Series B
$9M
Series B (2022): $9M with participation from Triventures, New Age Ventures, Mid Atlantic Bio Angels, MEDA Angels, and Robin Hood Ventures
Key Investors in FEMSelect
Triventures
A global venture capital fund specializing in early-stage companies with innovative breakthroughs in healthcare, bio-convergence, and data-driven technologies.
New Age Ventures
A globally active venture studio that invests in a diverse range of sectors including healthcare, digital health, and applied AI, focusing on strong founder-market fit.
Mid Atlantic Bio Angels
An angel investor group dedicated to funding new and emerging life science companies globally, providing both capital and strategic feedback to entrepreneurs.
What's next for FEMSelect?
Looking ahead, FEMSelect is poised to leverage its recent capital influx to broaden its clinical reach and solidify its market leadership. The strategic roadmap likely includes expanding the availability of the EnPlace procedure across new healthcare systems and investing in further clinical validation to support long-term outcomes. As the company transitions from its current growth phase into a more mature enterprise-level operation, the focus will remain on scaling its commercial infrastructure and fostering deeper partnerships within the medical community. By maintaining its commitment to innovation in women's health, FEMSelect is well-equipped to navigate the complexities of the healthcare market and deliver sustained value to its stakeholders.
See full FEMSelect company page
